taurine in diabetes

Phase 3

Recruiting

• Conditions: Type 2 diabetes.; Type 2 diabetes mellitus

• Registration Number: IRCT20121028011288N17
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Patients with Type 2 Diabetes
Patients who use glucose lowering oral medications are well controlled by their blood glucose levels.Body mass index 35-25 kg /m 2 will be included in the study.age range from 20-60 years

Exclusion Criteria

Use of multi-vitamin and mineral supplements over the past 3 months.Taking corticosteroids and non-steroidal anti-inflammatory drugs.Taking insulin Patients with polycystic ovary syndrome Patients with chronic diseases such as cardiovascular, renal and hepatic disorders, and hypothyroidism and hyperthyroidism Having certain physiological conditions such as pregnancy and lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pentosidine. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of pentosidin via ELISA kit.;Soluble receptor of advanced glycation end products. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of soluble receptor of advanced glycation end products via ELISA kit.;Methylglyoxal. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of methylglyoxal via ELISA kit.